Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

ClinicalTrials.gov ID: NCT06118086

Public ClinicalTrials.gov record NCT06118086. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

Study identification

NCT ID: NCT06118086
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Remix Therapeutics; Industry
Enrollment: 125 participants

Conditions and interventions

Conditions

Interventions

REM-422 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 19, 2023
Primary completion: Sep 29, 2027
Completion: Sep 29, 2027
Last update posted: Jun 23, 2026

2023 – 2027

United States locations

U.S. sites: 7
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
University of California San Francisco Helen Diller Comprehensive Cancer Center	San Francisco	California	94143	Recruiting
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
Dana Farber Cancer Research Institute	Boston	Massachusetts	02215	Recruiting
University of Michigan Rogel Cancer Center	Ann Arbor	Michigan	48109	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Sarah Cannon Research Institute	Nashville	Tennessee	37203	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06118086, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 23, 2026 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06118086 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →